Related Research Articles
Radiation therapy or radiotherapy, often abbreviated RT, RTx, or XRT, is a therapy using ionizing radiation, generally provided as part of cancer treatment to control or kill malignant cells and normally delivered by a linear accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.
External beam radiotherapy (EBRT) is the most common form of radiotherapy. The patient sits or lies on a couch and an external source of ionizing radiation is pointed at a particular part of the body. In contrast to brachytherapy and unsealed source radiotherapy, in which the radiation source is inside the body, external beam radiotherapy directs the radiation at the tumour from outside the body. Orthovoltage ("superficial") X-rays are used for treating skin cancer and superficial structures. Megavoltage X-rays are used to treat deep-seated tumours, whereas megavoltage electron beams are typically used to treat superficial lesions extending to a depth of approximately 5 cm. X-rays and electron beams are by far the most widely used sources for external beam radiotherapy. A small number of centers operate experimental and pilot programs employing beams of heavier particles, particularly protons, owing to the rapid dropoff in absorbed dose beneath the depth of the target.
A radiation oncologist is a specialist physician who uses ionizing radiation in the treatment of cancer. Radiation oncology is one of the three primary specialties, the other two being surgical and medical oncology, involved in the treatment of cancer. Radiation can be given as a curative modality, either alone or in combination with surgery and/or chemotherapy. It may also be used palliatively, to relieve symptoms in patients with incurable cancers. A radiation oncologist may also use radiation to treat some benign diseases, including benign tumors. In some countries, radiotherapy and chemotherapy are controlled by a single oncologist who is a "clinical oncologist". Radiation oncologists work closely with other physicians such as surgical oncologists, interventional radiologists, internal medicine subspecialists, and medical oncologists, as well as medical physicists and technicians as part of the multi-disciplinary cancer team. Radiation oncologists undergo four years of oncology-specific training whereas oncologists who deliver chemotherapy have two years of additional training in cancer care during fellowship after internal medicine residency in the United States.
Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachy is Greek for short. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, esophageal and skin cancer and can also be used to treat tumours in many other body sites. Treatment results have demonstrated that the cancer-cure rates of brachytherapy are either comparable to surgery and external beam radiotherapy (EBRT) or are improved when used in combination with these techniques. Brachytherapy can be used alone or in combination with other therapies such as surgery, EBRT and chemotherapy.
In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.
Elekta is a global Swedish company that develops and produces radiation therapy and radiosurgery-related equipment and clinical management for the treatment of cancerand brain disorders. Elekta has a global presence in more than 120 countries, with over 40 offices around the world and about 4,700 employees.
In radiotherapy, radiation treatment planning (RTP) is the process in which a team consisting of radiation oncologists, radiation therapist, medical physicists and medical dosimetrists plan the appropriate external beam radiotherapy or internal brachytherapy treatment technique for a patient with cancer.
Tomotherapy is a radiation therapy modality, in which the patient is scanned across a modulated strip-beam, so that only one “slice” of the target is exposed at any one time by the linear accelerator (linac) beam. The three components distinctive to this modality are: (1) a collimator pair that defines the length of the strip, (2) a binary multileaf collimator whose leaves open and close during treatment to modulate the strip’s intensity, and (3) a couch that scans the patient across the beam at a fixed speed during the treatment delivery.
Intraoperative radiation therapy (IORT) is radiation therapy that is administered during surgery directly in the operating room.
Image-guided radiation therapy is the process of frequent imaging, during a course of radiation treatment, used to direct the treatment, position the patient, and compare to the pre-therapy imaging from the treatment plan. Immediately prior to, or during, a treatment fraction, the patient is localized in the treatment room in the same position as planned from the reference imaging dataset. An example of IGRT would include comparison of a cone beam computed tomography (CBCT) dataset, acquired on the treatment machine, with the computed tomography (CT) dataset from planning. IGRT would also include matching planar kilovoltage (kV) radiographs or megavoltage (MV) images with digital reconstructed radiographs (DRRs) from the planning CT.
Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.
Brachytherapy is a type of radiotherapy, or radiation treatment, offered to certain cancer patients. There are two types of brachytherapy – high dose-rate (HDR) and low dose-rate (LDR). LDR brachytherapy is the one most commonly used to treat prostate cancer. It may be referred to as 'seed implantation' or it may be called 'pinhole surgery'.
Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship based interventions. These interventions are focused on five domains including: physical symptoms, psychological symptoms, surveillance, health promotion and care coordination. However, a published review has found only high levels of evidence for interventions that target physical and psychological symptom management and health promotion, with no reviews of interventions for either care coordination or surveillance. The favored treatment option depends on the stage of the disease, the Gleason score, and the PSA level. Other important factors include the man's age, his general health, and his feelings about potential treatments and their possible side-effects. Because all treatments can have significant side-effects, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations.
Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.
Gujarat Cancer & Research Institute (GCRI) is a state owned cancer research institute in Gujarat, India. It was established in 1972. It is one of the 25 government funded Regional Cancer Centres in India.
Professor Minesh P. Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
Timo Joensuu is a Finnish oncologist, associate professor of clinical oncology in University of Helsinki, researcher of new cancer treatments and developer of an internationally new hospital concept. He is a co-founder of Docrates Cancer Center in Helsinki and was its clinical director until 2014, after which he has been concentrating mostly on clinical work with the patients as the chief oncologist.
Gel dosimeters, also called Fricke gel dosimeters, are manufactured from radiation sensitive chemicals that, upon irradiation with ionising radiation, undergo a fundamental change in their properties as a function of the absorbed radiation dose.
Jay Steven Loeffler is an American physician at Massachusetts General Hospital where he has served as Chair of the Department of Radiation Oncology since 2000. He is the Herman and Joan Suit Professor of Radiation Oncology and Professor of Neurosurgery at Harvard Medical School.
Dr. Daniel Przybysz is a Brazilian Radiation-Oncologist. His practice is mainly focused on lung cancer treatment and high technology approaches toward better patient care.
References
- ↑ Docrates Sairaala - taloustiedot - Fonecta Finder
- ↑ Docrates Oy - Docrates
- ↑ "Suomalainen syöpähoitaja vetää puoleensa potilaita ympäri maailmaa". Kauppalehti. 2016-08-25 [2010].
- ↑ Wolff, HA; Wagner, DM; Christiansen, H; Hess, CF; Vorwerk, H (2010). "Single fraction radiosurgery using Rapid Arc for treatment of intracranial targets". Radiat Oncol. 5: 77. doi:10.1186/1748-717X-5-77. PMC 2949676 . PMID 20836871.
- ↑ Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments - Worldnews.com
